Search

Displaying results 4231 - 4240 of 9714 in total
  1. Drug

    Elenbecestat

    go.drugbank.com/drugs/DB15391
    Investigational

    Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease).

  2. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction. … [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization

  3. Drug

    Ziritaxestat

    go.drugbank.com/drugs/DB15403
    Investigational

    Ziritaxestat is under investigation in clinical trial NCT03798366 (A Clinical Study to Test How Effective and Safe GLPG1690 is for Patients With Systemic Sclerosis).

    Synonyms: 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile
  4. Drug

    Ladiratuzumab vedotin

    go.drugbank.com/drugs/DB15409
    Investigational

    Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).

  5. Drug

    ABP-700

    go.drugbank.com/drugs/DB15411
    Investigational

    ABP-700 is under investigation in clinical trial NCT02800590 (Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy).

    Categories: GABA-A Receptor Agonists
  6. Drug

    Cetrelimab

    go.drugbank.com/drugs/DB15421
    Investigational

    Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD

  7. Drug

    Pinatuzumab vedotin

    go.drugbank.com/drugs/DB15432
    Investigational

    Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or

  8. Drug

    AVI-7537

    go.drugbank.com/drugs/DB15433
    Investigational

    [L46207] AVI-7537 is under investigation in clinical trial NCT01593072 (A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers).

  9. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. … However, patients with certain types of B-cell lymphoma, such as follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) or aggressive B-cell lymphoma, have a high probability of relapse or recurrence

  10. Drug

    SOBI-003

    go.drugbank.com/drugs/DB15451
    Investigational

    SOBI-003 is a chemically modified variant of a recombinant human sulfamidase. … It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).